RADIOPHARM THERANOSTICS LTD (RADX) Fundamental Analysis & Valuation

NASDAQ:RADX

Current stock price

4.795 USD
+0.08 (+1.59%)
Last:

This RADX fundamental analysis includes valuation metrics, fair value assessment, financial health analysis, profitability trends, growth metrics and dividend sustainability analysis.

1

1. RADX Profitability Analysis

1.1 Basic Checks

  • In the past year RADX has reported negative net income.
  • RADX had a negative operating cash flow in the past year.
  • In the past 5 years RADX always reported negative net income.
  • In the past 5 years RADX always reported negative operating cash flow.
RADX Yearly Net Income VS EBIT VS OCF VS FCFRADX Yearly Net Income VS EBIT VS OCF VS FCFYearly Net Income VS EBIT VS OCF VS FCF 2021 2022 2023 2024 2025 -10M -20M -30M -40M

1.2 Ratios

  • The Return On Assets of RADX (-49.29%) is comparable to the rest of the industry.
  • The Return On Equity of RADX (-86.80%) is comparable to the rest of the industry.
Industry RankSector Rank
ROA -49.29%
ROE -86.8%
ROIC N/A
ROA(3y)-51.73%
ROA(5y)-328.87%
ROE(3y)-110.14%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
RADX Yearly ROA, ROE, ROICRADX Yearly ROA, ROE, ROICYearly ROA, ROE, ROIC 2021 2022 2023 2024 2025 0 500 -500 -1K

1.3 Margins

  • The Gross Margin of RADX (10.28%) is better than 71.59% of its industry peers.
  • RADX does not have Profit Margin and Operating Margin available, so we won't be analyzing them here.
Industry RankSector Rank
OM N/A
PM (TTM) N/A
GM 10.28%
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
RADX Yearly Profit, Operating, Gross MarginsRADX Yearly Profit, Operating, Gross MarginsYearly Profit, Operating, Gross Margins 2021 2022 2023 2024 2025 0 -5K -10K -15K

More info and screens

ROAROEROICOperating and Profit MarginShow most profitable peers

6

2. RADX Health Analysis

2.1 Basic Checks

  • RADX does not have a ROIC to compare to the WACC, probably because it is not profitable.
  • Compared to 1 year ago, RADX has more shares outstanding
  • RADX has no outstanding debt. Therefor its Debt/Equity and Debt/FCF ratios are 0 and belong to the best of the industry.
RADX Yearly Shares OutstandingRADX Yearly Shares OutstandingYearly Shares Outstanding 2021 2022 2023 2024 2025 1M 2M 3M 4M 5M
RADX Yearly Total Debt VS Total AssetsRADX Yearly Total Debt VS Total AssetsYearly Total Debt VS Total Assets 2021 2022 2023 2024 2025 20M 40M 60M 80M

2.2 Solvency

  • RADX has an Altman-Z score of -2.67. This is a bad value and indicates that RADX is not financially healthy and even has some risk of bankruptcy.
  • RADX has a Altman-Z score of -2.67. This is comparable to the rest of the industry: RADX outperforms 47.02% of its industry peers.
  • There is no outstanding debt for RADX. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Altman-Z -2.67
ROIC/WACCN/A
WACC9.38%
RADX Yearly LT Debt VS Equity VS FCFRADX Yearly LT Debt VS Equity VS FCFYearly LT Debt VS Equity VS FCF 2021 2022 2023 2024 2025 0 20M -20M 40M 60M

2.3 Liquidity

  • A Current Ratio of 3.01 indicates that RADX has no problem at all paying its short term obligations.
  • With a Current ratio value of 3.01, RADX is not doing good in the industry: 64.30% of the companies in the same industry are doing better.
  • RADX has a Quick Ratio of 3.01. This indicates that RADX is financially healthy and has no problem in meeting its short term obligations.
  • The Quick ratio of RADX (3.01) is worse than 62.38% of its industry peers.
Industry RankSector Rank
Current Ratio 3.01
Quick Ratio 3.01
RADX Yearly Current Assets VS Current LiabilitesRADX Yearly Current Assets VS Current LiabilitesYearly Current Assets VS Current Liabilites 2021 2022 2023 2024 2025 10M 20M 30M

More info and screens

WACCDebt/EquityHow to determine the health of a companyAltman-Z scoreShow peers with great health

5

3. RADX Growth Analysis

3.1 Past

  • RADX shows a strong growth in Earnings Per Share. In the last year, the EPS has been growing by 76.17%, which is quite impressive.
  • RADX shows a strong growth in Revenue. In the last year, the Revenue has grown by 116.02%.
EPS 1Y (TTM)76.17%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%25.49%
Revenue 1Y (TTM)116.02%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%0.14%

3.2 Future

  • RADX is expected to show a strong growth in Earnings Per Share. In the coming years, the EPS will grow by 22.04% yearly.
  • Based on estimates for the next years, RADX will show a very strong growth in Revenue. The Revenue will grow by 111.59% on average per year.
EPS Next Y-10.26%
EPS Next 2Y1.27%
EPS Next 3Y14.8%
EPS Next 5Y22.04%
Revenue Next Year-100%
Revenue Next 2Y42.64%
Revenue Next 3Y123.94%
Revenue Next 5Y111.59%

3.3 Evolution

RADX Yearly Revenue VS EstimatesRADX Yearly Revenue VS EstimatesYearly Revenue VS Estimates 2023 2024 2025 2027 2028 2029 2030 2031 2032 2033 200M 400M 600M
RADX Yearly EPS VS EstimatesRADX Yearly EPS VS EstimatesYearly EPS VS Estimates 2022 2023 2024 2025 2026 2027 2028 2029 2030 2031 2032 0 -20 -40

More info and screens

Find the best growth stocksShow best growing peers

0

4. RADX Valuation Analysis

4.1 Price/Earnings Ratio

  • The Price/Earnings Ratio is negative for RADX. In the last year negative earnings were reported.
  • Also next year RADX is expected to report negative earnings again, which makes the also the Forward Price/Earnings Ratio negative.
Industry RankSector Rank
PE N/A
Fwd PE N/A
RADX Price Earnings VS Forward Price EarningsRADX Price Earnings VS Forward Price Earnings ChartPrice Earnings - Forward Price Earnings PE FPE 0 10 20 30 40 50

4.2 Price Multiples

Industry RankSector Rank
P/FCF N/A
EV/EBITDA N/A
RADX Per share dataRADX EPS, Sales, OCF, FCF, BookValue per sharePer Share Data Per Share 0 2 -2 4 -4 -6

4.3 Compensation for Growth

  • A more expensive valuation may be justified as RADX's earnings are expected to grow with 14.80% in the coming years.
PEG (NY)N/A
PEG (5Y)N/A
EPS Next 2Y1.27%
EPS Next 3Y14.8%

More info and screens

Price/EarningsPrice/FCFFCF per shareEV/EBITDAPEG RATIOShow best valued peers

0

5. RADX Dividend Analysis

5.1 Amount

  • RADX does not give a dividend.
Industry RankSector Rank
Dividend Yield 0%

More info and screens

Find the best dividend stocksShow peers with best dividend

RADX Fundamentals: All Metrics, Ratios and Statistics

RADIOPHARM THERANOSTICS LTD

NASDAQ:RADX (3/20/2026, 8:18:43 PM)

4.795

+0.08 (+1.59%)

Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupPharmaceuticals, Biotechnology & Life Sciences
GICS IndustryBiotechnology
Earnings (Last)02-26
Earnings (Next)N/A
Inst Owners10.41%
Inst Owner ChangeN/A
Ins Owners7.1%
Ins Owner ChangeN/A
Market Cap37.30M
Revenue(TTM)3.64M
Net Income(TTM)-44.94M
Analysts80
Price Target5.17 (7.82%)
Short Float %0.49%
Short Ratio0.53
Dividend
Industry RankSector Rank
Dividend Yield 0%
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)N/A
Avg EPS beat(2)N/A
Min EPS beat(2)N/A
Max EPS beat(2)N/A
EPS beat(4)N/A
Avg EPS beat(4)N/A
Min EPS beat(4)N/A
Max EPS beat(4)N/A
EPS beat(8)N/A
Avg EPS beat(8)N/A
EPS beat(12)N/A
Avg EPS beat(12)N/A
EPS beat(16)N/A
Avg EPS beat(16)N/A
Revenue beat(2)N/A
Avg Revenue beat(2)N/A
Min Revenue beat(2)N/A
Max Revenue beat(2)N/A
Revenue beat(4)N/A
Avg Revenue beat(4)N/A
Min Revenue beat(4)N/A
Max Revenue beat(4)N/A
Revenue beat(8)N/A
Avg Revenue beat(8)N/A
Revenue beat(12)N/A
Avg Revenue beat(12)N/A
Revenue beat(16)N/A
Avg Revenue beat(16)N/A
PT rev (1m)-3.6%
PT rev (3m)8.09%
EPS NQ rev (1m)-45.77%
EPS NQ rev (3m)-45.77%
EPS NY rev (1m)-45.77%
EPS NY rev (3m)-42.46%
Revenue NQ rev (1m)N/A
Revenue NQ rev (3m)N/A
Revenue NY rev (1m)N/A
Revenue NY rev (3m)N/A
Valuation
Industry RankSector Rank
PE N/A
Fwd PE N/A
P/S 14.52
P/FCF N/A
P/OCF N/A
P/B 1.02
P/tB 7.88
EV/EBITDA N/A
EPS(TTM)-4.93
EYN/A
EPS(NY)-6.18
Fwd EYN/A
FCF(TTM)-3.37
FCFYN/A
OCF(TTM)-3.37
OCFYN/A
SpS0.33
BVpS4.7
TBVpS0.61
PEG (NY)N/A
PEG (5Y)N/A
Graham NumberN/A
Profitability
Industry RankSector Rank
ROA -49.29%
ROE -86.8%
ROCE N/A
ROIC N/A
ROICexc N/A
ROICexgc N/A
OM N/A
PM (TTM) N/A
GM 10.28%
FCFM N/A
ROA(3y)-51.73%
ROA(5y)-328.87%
ROE(3y)-110.14%
ROE(5y)N/A
ROIC(3y)N/A
ROIC(5y)N/A
ROICexc(3y)N/A
ROICexc(5y)N/A
ROICexgc(3y)N/A
ROICexgc(5y)N/A
ROCE(3y)N/A
ROCE(5y)N/A
ROICexgc growth 3YN/A
ROICexgc growth 5YN/A
ROICexc growth 3YN/A
ROICexc growth 5YN/A
OM growth 3YN/A
OM growth 5YN/A
PM growth 3YN/A
PM growth 5YN/A
GM growth 3YN/A
GM growth 5YN/A
F-Score4
Asset Turnover0.04
Health
Industry RankSector Rank
Debt/Equity 0
Debt/FCF N/A
Debt/EBITDA N/A
Cap/Depr N/A
Cap/Sales N/A
Interest Coverage N/A
Cash Conversion N/A
Profit Quality N/A
Current Ratio 3.01
Quick Ratio 3.01
Altman-Z -2.67
F-Score4
WACC9.38%
ROIC/WACCN/A
Cap/Depr(3y)N/A
Cap/Depr(5y)N/A
Cap/Sales(3y)N/A
Cap/Sales(5y)N/A
Profit Quality(3y)N/A
Profit Quality(5y)N/A
High Growth Momentum
Growth
EPS 1Y (TTM)76.17%
EPS 3YN/A
EPS 5YN/A
EPS Q2Q%25.49%
EPS Next Y-10.26%
EPS Next 2Y1.27%
EPS Next 3Y14.8%
EPS Next 5Y22.04%
Revenue 1Y (TTM)116.02%
Revenue growth 3YN/A
Revenue growth 5YN/A
Sales Q2Q%0.14%
Revenue Next Year-100%
Revenue Next 2Y42.64%
Revenue Next 3Y123.94%
Revenue Next 5Y111.59%
EBIT growth 1Y-8.19%
EBIT growth 3YN/A
EBIT growth 5YN/A
EBIT Next Year15.81%
EBIT Next 3Y28.13%
EBIT Next 5YN/A
FCF growth 1Y-52.08%
FCF growth 3YN/A
FCF growth 5YN/A
OCF growth 1Y-61.75%
OCF growth 3YN/A
OCF growth 5YN/A

RADIOPHARM THERANOSTICS LTD / RADX Fundamental Analysis FAQ

Can you provide the ChartMill fundamental rating for RADIOPHARM THERANOSTICS LTD?

ChartMill assigns a fundamental rating of 3 / 10 to RADX.


What is the valuation status for RADX stock?

ChartMill assigns a valuation rating of 0 / 10 to RADIOPHARM THERANOSTICS LTD (RADX). This can be considered as Overvalued.


Can you provide the profitability details for RADIOPHARM THERANOSTICS LTD?

RADIOPHARM THERANOSTICS LTD (RADX) has a profitability rating of 1 / 10.


How financially healthy is RADIOPHARM THERANOSTICS LTD?

The financial health rating of RADIOPHARM THERANOSTICS LTD (RADX) is 6 / 10.